Abstract:As a novel co-receptor for vascular endothelial growth factor (VEGF), neuropilin receptor type-1 (NRP-1) is overexpressed in several cancers and metastases, and serves as an attractive target for cancer molecular imaging and therapy. Previous single photon emission computerized tomography (SPECT) studies demonstrated that the small NRP-1-targeting peptides 99mTc-MA-ATWLPPR and 99mTc-CK3 showed poor tumor imaging quality, because of their rapid blood clearance and very low tumor uptake. Compared with small peptides, monoclonal antibodies (mAbs) can improve imaging of NRP-1-expression, due to their high affinity, specificity and slow extraction. A6-11-26 is a novel monoclonal antibody against NRP-1 b1b2 domain that exhibits inhibition of tumor growth in NPR-1-expressing preclinical models. The aim of the present study was to develop the 131I-labeled anti-NRP-1 monoclonal antibody A6-11-26 as a SPECT probe for imaging of NRP-1-positive tumor. An anti-NRP-1 monoclonal antibody (A6-11-26) was produced by hybridomas and was labeled with iodine-131 by the iodogen method. In vitro, the radiolabeling efficiency, radiochemical purity, immunoreactive fraction and stability were assessed. Binding affinity and specificity of 131I‑A6-11-26 to NRP-1 were evaluated using human glioblastoma U87MG cells. In vivo, biodistribution and SPECT/CT studies were conducted on mice bearing U87MG xenografts after the injection of 131I-A6-11-26 with or without co-injection of unlabeled A6-11-26 antibody. A6-11-26 was generated successfully by hybridoma with high purity (>95%) and was labeled with iodine-131 within 60 min with high labelling efficiency (95.46±3.34%), radiochemical purity (98.23±1.41%). 131I-A6-11-26 retained its immunoreactivity and also displayed excellent stability in mouse serum and PBS solution during 1 to 96 h. Cell uptake assays showed high NRP-1-specific uptake (15.80±1.30% applied activity at 6 h) in U87MG cells. 131I-A6-11-26 bound to NRP-1 with low nanomolar affinity (KD=1.67±0.14 nM) in U87MG cells. In vivo, biodistribution study demonstrated targeting of U87MG glioma xenografts was NRP-1 specific. The tumor uptake was 6.00±1.24%ID/g at 24 h, and the tumor to muscle ratio was 3.20±0.30 at 24 h, and reached the highest level of 6.13±0.24 at 120 h after injection. SPECT imaging studies revealed that 131I-A6-11-26 could clearly identify U87MG tumors with good contrast, especially at 72-120 h after injection. The present study demonstrates that 131I-A6-11-26 is capable of detecting lesions in an NRP-1-expressing tumor with high target selectivity, and may offer a promising SPECT agent for NRP-1 expression positive tumor and encourage further investigation.

Study of Novel Peptide Probe 131 I-RRL for Tumor Molecular Imaging

A novel radioiodinated peptide of arginine-arginine-leucine(RRL)for biodistribution and tumor angiogenic endothelium imaging

The Further Study on Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovascularization As Well As Tumor Cells in Molecular Tumor Imaging

A Novel 99mTc-Labeled Molecular Probe for Tumor Angiogenesis Imaging in Hepatoma Xenografts Model:A Preliminary Study

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Design, Synthesis and Iodination of an Arg‐Arg‐Leu Peptide for Potential Use As an Imaging Agent for Human Prostate Carcinoma

Technetium-99m- Arg-Arg-Leu(g2), a Modified Peptide Probe Targeted to Neovascularization in Molecular Tumor Imaging.

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

Validation study of 131I-RRL: Assessment of biodistribution, SPECT imaging and radiation dosimetry in mice

Use of Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovasculari- Zation As Well As Tumor Cells in Molecular Tumor Imaging.

Noninvasive PET Imaging of a Ga-68-Radiolabeled RRL-Derived Peptide in Hepatocarcinoma Murine Models

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice.

SPECT Imaging of Neuropilin Receptor Type-1 Expression with 131I-Labeled Monoclonal Antibody.

Detection of Pulmonary Metastases with the Novel Radiolabeled Molecular Probe, (99M)tc-Rrl.

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Study on pharmacokinetics and acute toxicity of new molecular probe 99 m Tc-RRL

Progress and prospect of molecular probes of radionuclide tracing targeted tumor angiogenesis

18F Labeled RGD‐A7R Peptide for Dual Integrin and VEGF‐targeted Tumor Imaging in Mice Bearing U87MG Tumors

A Novel Tc-99m-labeled and MAG<sub>3</sub>-chelated Arginine-Arginine-Leucine containing Peptide for Tumor Imaging in Hepatoma Xenografts Model